natgillin/translations-raw huggingface dataset:
Trombocytopeni: Alvorlig (trombocyttal under 25 x 109/l) hos 25 % af patienterne (8 % af behandlingerne), moderat (trombocyttal mellem 25,0 og 50,0 x 109/l) hos 25 % af patienterne (15 % af behandlingerne).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocytopeni: Alvorlig trombocytopeni (grad 4 - trombocyttal mindre end 10 x 109/l) sås hos 6 % af patienterne i 2 % af behandlingsperioderne.
Thrombocytopenia: Severe thrombocytopenia (Grade 4 - platelets less than 10 x 109/l) occurred in 6 % of patients in 2 % of courses.
Trombocytopeni: Alvorlig trombocytopeni (trombocyttal under 25 x 109/l) hos 25 % af patienterne (8 % af behandlingerne), moderat (trombocyttal mellem 25,0 og 50,0 x 109/l) hos 25 % af patienterne (15 % af behandlingerne).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15 % of courses).
Trombocytopeni; (G3/4: 0,6 %);
(G3/4: 0.6%);
Trombocytopeni; (G3/4: 0,6 %); Febril neutropeni
Febrile neutropenia (G3/4: NA)
Trombocytopenia
Thrombocytopeni aa
Trombocytopenia Leukocytosea
Thrombocytopeniaa Leukocytosisa
Trombocytopenib
Thrombocytopeniab
trombocytopenib, lymfopenib
thrombocytopeniab, lymphopeniab
Trombocytopenib,c
Thrombocytopeniab,c
trombocytopenisk
thrombocytopenic
Trombocytose
enia
Trombocytose
Thrombocy
Trombocytose
Thrombocyt
Trombocytt er
Platelets
Trombocyttal
Platelets
Trombocyttal
Thrombocyte count
Trombocyttal (x 109/l)
Platelet count (x 109/l)
Trombocyttal (x109/l)
Platelet Count (x109/L)
Trombocyttal < 25 x 109/l
Platelet count <25 x 109/l
Trombocyttal < 30.000 x 106/l, selvom trombocyttallet øges ved transfusioner
Platelet count < 30,000 x 106/l, even if the platelet count is increased after transfusions
Trombocyttal bør derfor monitoreres nøje.
Platelet counts should therefore be monitored closely.
Trombocyttal på <100 x 109/l ved udgangsniveauet, der stiger med >50 % eller til en værdi på >100 x 109/l efter udgangsniveauet
Platelet counts ≤100x109/l at baseline to >50% increase or >100x109/l post baseline
Trombocyttal skal være ≥ 100 x 109 celler/l og absolut neutrofiltal (ANC) skal være
Platelet counts should be ≥ 100,000 cells/μL and the absolute neutrophils count (ANC) should be ≥ 1,500 cells/μL
Trombocyttal skal være ≥ 100 x 109 celler/l, og absolut neutrofiltal (ANC) skal være
Platelet counts should be ≥ 100,000 cells/μl and the absolute neutrophils count (ANC) should be ≥ 1,500 cells/μl
Trombocyttal skal være ≥ 70 x 109/l, og absolut neutrofiltal skal være ≥ 1,0 x 109/l
Platelet counts should be ≥ 70 x 109/l and the absolute neutrophils count should be ≥ 1.0 x 109/l
Trombocyttal skal være ≥ 75 x 109 celler/l hos patienter med infiltreret knoglemarv eller sekvestration af milten.
Platelet counts should be ≥ 75,000 cells/μL in patients with bone marrow infiltration or splenic sequestration
Trombocyttal skal være ≥ 75x 109 celler/l hos patienter med infiltreret knoglemarv eller sekvestration af milten.
Platelet counts should be ≥ 75,000 cells/μL in patients with bone marrow infiltration or splenic sequestration
Trombocyttal under 100 x 109/l blev set hos 7 % af de patienter, som blev behandlet med MIRCERA, og hos 4 % af de patienter, som blev behandlet med andre ESAs.
Platelet counts below 100 x 109/l were observed in 7% of patients treated with MIRCERA and 4% of patients treated with other ESAs.
Trombocyttal ved baseline (× 109/l), median (min.; maks.)
Baseline platelet count (× 109/L), median (, min, max )
trombocyttal ≥ 100 x 109/l common toxicity criteria (CTC, kriterium for gradering af bivirkninger) for ikke-hæmatologisk toksicitet ≤ grad 1 (undtagen for alopeci, kvalme og opkastning)
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
trombocyttal ≥ 100 x 109/l common toxicity criteria (CTC, kriterium for gradering af bivirkninger) ikke-hæmatologisk toksicitet ≤ Grad 1 (undtagen for alopeci, kvalme og opkastning)
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
Trombocyttal ≥ 90.000/mm3
Platelet count ≥ 90,000/mm3
Trombocyttal 90.000/mm3
Platelet count  90,000/mm3
Trombocyttallene for patienter med ITP, som modtog
The platelet counts of ITP patients who received
Trombocyttallene for patienter med ITP, som modtog 6 ugentlige doser på 1 eller 3 µg/kg romiplostim, lå for de fleste patienters vedkommende inden for området 50 til 450 x 109/l.
The platelet counts of ITP patients who received weekly doses of 1 or 3 µg/kg of romiplostim were within the range of 50 to 450 x 109/l for most patients.
Trombocyttallene skal derfor monitoreres nøje.
Platelet counts should therefore be monitored closely.
Trombocyttallet bør derfor monitoreres nøje.
Platelet counts should therefore be monitored closely.
Trombocyttallet bør monitoreres mindst en gang om ugen i 2-3 uger, når eltrombopag administreres samtidigt med ciclosporin.
Platelet count should be monitored at least weekly for 2 to 3 weeks when eltrombopag is co- administered with ciclosporin.
Trombocyttallet bør monitoreres nøje, især i de første få uger under behandlingen med filgrastim.
Platelet counts should be monitored closely, especially during the first few weeks of filgrastim therapy.
Trombocyttallet skal monitoreres tæt for at sikre den mest hensigtsmæssige dosis af eltrombopag, når lopinavir/ritonavir- behandling påbegyndes eller stoppes.
Platelet count should be closely monitored in order to ensure appropriate medical management of the dose of eltrombopag when lopinavir/ritonavir therapy is initiated or discontinued.
Trombocyttallet var lavest på dag 11 i hver cyklus af bortezomib-behandlingen og var typisk vendt tilbage til baseline- niveau ved den næste cyklus.
Platelets were lowest at Day 11 of each cycle of bortezomib treatment and typically recovered to baseline by the next cycle.
Trombocyttallet var lavest på dag 11 i hver cyklus af VELCADE-behandlingen og var typisk vendt tilbage til baseline- niveau ved den næste cyklus.
Platelets were lowest at Day 11 of each cycle of VELCADE treatment and typically recovered to baseline by the next cycle.
Trombocyttallet vender tilbage til
Platelet count return to ≥50 x 109/l
trombocytter
Platelet count decreased
Trombocytter (x 109/l)
Platelets (x 109/l)
Trombocytter < 25 x 109/l trombocytopeni
Platelets < 25 x 109/l thrombocytopenia
Trombocytter < 50 x 109/l
Platelets < 50×109/L
Trombocytter < 50 x 109/l trombocytopeni kompliceret af blødning eller som kræver blod- eller trombocyttransfusion
Platelets < 50 x 109/l thrombocytopenia complicated by haemorrhage or requiring blood or platelet transfusion
Trombocytter < 75 x 109/l
Platelets < 75 x 109/l
trombocytter <10 x 109/l
and/or platelets < 10 x 109/1
trombocytter <10 x 109/l
platelets < 10 x 109/1
Trombocytter  100.000/mm3
Platelets  100,000/mm3(see section 4.4).
Trombocytter  100.000/mm3
Platelets  100,000/mm3
Trombocytæmi
Neutropaenia
Trombocytæmi (inkl. forhøjet trombocyttal)A
Thrombocythemia (incl. platelet count increased)A
Trombocytæmi, eosinofil, forhøjet international normalised ratio (INR)
Thrombocythaemia, eosinophilia, international normalised ratio (INR) increased
Tromboemboli
Thrombo-embolism
Tromboemboli
Thromboembolis
Tromboemboli (inklusive
embolism and
Tromboemboli (inklusive
Hepatitis (including
Tromboemboli (inklusive
Pancreatitis11
Tromboemboli (inklusive
Thromboembolis m (including
Tromboemboli (inklusive
Thromboembolism (including
Tromboemboli (inklusive
Thromboembolism (including pulmonary
Tromboemboli (inklusive lungeemboli og dyb venetrombose) (se pkt.
Thromboembol ism (including pulmonary embolism and deep vein thrombosis) (see section
Tromboemboli (lungeemboli, dyb venetrombose)*
Thromboembolism (pulmonary embolism, deep vein thrombosis)
Tromboemboli (problemer med blodpropper i blodkarene) kan i yderst sjældne tilfælde forekomme, normalt i forbindelse med alvorligt OHSS.
Thromboembolism (problems with blood clots in the blood vessels) may occur very rarely, usually associated with severe OHSS.
Tromboemboli:
Thromboembolism:
Tromboemboliske hændelser
Thromboembolic event
Tromboemboliske hændelser ITP-patienter
Thromboembolic events ITP patients
Tromboemboliske hændelser Skema over bivirkninger
Thromboembolic events Tabulated list of adverse reactions
Tromboemboliske hændelser – arterielle og venøse
Thromboembolic events - arterial and venous
Tromboemboliske hændelser, herunder lungeemboli
Thromboembolic events, including pulmonary embolism
Tromboemboliske hændelser, herunder lungeembolisme
Thromboembolic events, including pulmonary embolism
Tromboemboliske hændelser: Hos patienter med von Willebrands sygdom er der risiko for, at der opstår tromboemboliske hændelser - specielt hos patienter med kendte kliniske eller laboratorie- mæssige risikofaktorer.
Thromboembolic events: In patients with VWD, there is a risk of occurrence of thromboembolic events, particularly in patients with known clinical or laboratory risk factors.
tromboemboliske komplikationer 9 dage efter operationen.
Experience shows that in patients undergoing hip fracture surgery, the risk of VTE continues beyond 9 days after surgery.
tromboemboliske og iskæmiske tilstande, vaskulært betinget nedsat blodtryk, blødning, perifere kredsløbsforstyrrelser
thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders
Tromboemboliske reaktioner som myokardieinfarkt, slagtilfælde, lungeemboli og dyb venetrombose er set i sjældne tilfælde med i.v. og s.c. administration af immunglobulinpræparater.
Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis have been rarely observed with IV and SC administration of immunoglobulin products.
Tromboemboliske risici:
Thromboembolic risk:
Tromboflebit, ansigtsrødme, hedeture, hypertension, hypotension
thrombophlebitis, flushing, hot flush, hypertension, hypotension
tromboflebitis
thrombophlebitis
tromboflebitis, lymfangitis
thrombophlebitis, lymphangitis
Trombolytica: de veiligheid van de gelijktijdige toediening van clopidogrel, fibrine en non-fibrine specifieke trombolytica en heparine werd onderzocht bij patiënten met een acuut myocardinfarct.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Trombolytika: Sikkerheden ved samtidig administration af clopidogrel, fibrin eller non- fibrinspecifikke trombolytiske midler og hepariner blev vurderet hos patienter med akut myokardieinfarkt.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Trombolytika: Sikkerheden ved samtidig administration af clopidogrel, fibrin eller non-fibrinspecifikke trombolytiske midler og hepariner blev bedømt hos patienter AMI.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
trombose
thrombosis
trombose
thrombosis;
trombose (blodprop)
thrombosis
Trombose i a. femoralis Kapillært lækagesyndrom
Femoral artery thrombosis Capillary leak syndrome
Trombose i a. femoralis Systemisk vaskulært lækage- syndrom
Femoral artery thrombosis Capillary leak syndrome
Trombose i a. iliaca, hypovolæmisk shock, arterietrombose i ekstremitet, trombose, blussen, venetrombose i pelvis, tromboflebitis, flebitis, årebetændelse, ortostatisk hypotension, hæmatom, hyperæmi, hedeture,
Iliac artery thrombosis, hypovolaemic shock, arterial limb thrombosis, thrombosis, flushing, pelvic venous thrombosis, thrombophlebitis, phlebitis, phlebitis superficial, orthostatic hypotension, haematoma, hyperaemia, hot flush
trombose på injektionsstedet, inflammation på injektionsstedet, smerte på injektionsstedet, perifert ødem
injection site thrombosis, infusion site inflammation, injection site pain, peripheral oedema
Trombose*, lungeemboli*
Thrombosis*; Pulmonary embolism
Trombose/emboli*
Thrombosis/embolism
Tromboseprofylakse anbefales til patienter, der behandles med Kyprolis i kombination med dexamethason eller med lenalidomid og dexamethason, og skal baseres på en vurdering af patientens underliggende risici og kliniske status.
Thromboprophylaxis is recommended in patients being treated with Kyprolis in combination with dexamethasone or with lenalidomide and dexamethasone, and should be based on an assessment of the patient’s underlying risks and clinical status.
Trombotische Trombocytopenische Purpura (TTP)
Thrombotic Thrombocytopenic Purpura (TTP)
Trombotisk
Thrombotic
Trombotisk mikro- angiopati (inkl. trombotisk trombo- cytopenisk purpura og hæmolytisk uræmisk syndrom) †
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)
Trombotisk mikroangiopati
Thrombotic Microangiopathy
Trombotisk mikroangiopati (1)
Thrombotic microangiopathy (1)
Trombotisk mikroangiopati (inkl. trombotisk trombo- cytopenisk purpura og hæmolytisk uræmisk syndrom)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)
Trombotisk mikroangiopati (TMA), en sygdom hvor der er beskadigelse på de mindste blodkar.
Damage to the smallest blood vessels known as thrombotic microangiopathy (TMA).
Trombotisk mikroangiopati (TMA): Tilfælde af trombotisk mikroangiopati, der har manifesteret sig som trombotisk trombocytopenisk purpura (TTP) eller hæmolytisk uræmisk syndrom (HUS), herunder dødelige tilfælde, er indrapporteret i forbindelse med interferon-beta-præparater.
Thrombotic microangiopathy (TMA): Cases of thrombotic microangiopathy, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), including fatal cases, have been reported with interferon beta products.
Trombotisk mikroangiopati, herunder trombotisk trombocytopenisk purpura/hæmolytisk uræmisk syndrom*
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome
Trombotisk mikroangiopati, herunder trombotisk trombocytopenisk purpura/hæmolytisk uræmisk syndrom.*
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome
Trombotisk mikroangiopati, herunder trombotisk trombocytopenisk purpura/hæmolytisk uræmisk syndrom3
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome3
Trombotisk mikroangiopati, inkl. trombotisk trombocytopenisk purpura/hæmolytisk-uræmisk syndrom*
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome
Trombotisk mikroangiopatih, *
Thrombotic microangiopathyh,
trombotisk trombocyt openisk purpura, hypoprotro mbinæmi
thrombotic thrombocyto penic purpura, hypopro- thrombin- aemia
Trombotisk trombocytopenisk purpura (TTP)
Thrombotic Thrombocytopaenic Purpura (TTP)
Trombotisk trombocytopenisk purpura (TTP) (se pkt.
ection 4.4), aplastic
Trombotisk trombocytopenisk purpura (TTP) (se pkt.
purpura (TTP) (see
trombotisk trombocytopenisk purpura, hypoprotrombinæmi
thrombotic thrombocytopenic purpura, hypoprothrombinaemia
Trombotiske hændelser
Thromboembolic events
Trombotiske og emboliske hændelser Arteriel tromboemboli
Thrombotic and embolic events Arterial thromboembolic events
Trombotiske/Tromboemboliske hændelser (TEEs)
Thrombotic/Thromboembolic events (TEEs)
Trombotiske/tromboemboliske komplikationer
Thrombotic/Thromboembolic complications
Trometamol Edetinsyre Saccharose Dextran 70
Edetic Acid Sucrose Dextran 70
Trometamol Ethanol 96% Natriumchlorid
Trometamol Ethanol 96% Sodium chloride
Trometamol Natriumchlorid Hypromellose
Trometamol Sodium chloride Hypromellose
Trometamol natriumchlorid vand til injektionsvæsker polysorbat 80
Trometamol, sodium chloride, water for injections, polysorbate 80
Trometamol Polysorbat 80 Glutathion (reduceret)
Glutathione (reduced)
Trommehindelidelse
Tympanic membrane (eardrum) disorder.
Trommehindelidelser
Tympanic membrane disorder
tror De er gravid; eller
think you may be pregnant; or
Trough- plasmakoncentrationen af boceprevir blev reduceret, når det blev co- administreret med en NNRTI med en lignende metaboliseringsvej som nevirapin.
Plasma trough concentrations of boceprevir were decreased when administered with an NNRTI with a similar metabolic pathway as nevirapine.
trubehovedet (larynks), som kan gøre det svært at trække vejret kønsdele
voice-box (larynx), which may make breathing difficult genitals
TRUBERZI 100 mg filmovertrukne tabletter. eluxadolin
Truberzi 100 mg film-coated tablets. eluxadoline
TRUBERZI 75 mg filmovertrukne tabletter. eluxadolin
Truberzi 75 mg film-coated tablets. eluxadoline
Truberzi må ikke gives til patienter, der er i behandling med lægemidler, der kaldes potente OATP1B1- hæmmere (f.eks. cyclosporin, et lægemiddel, der virker på immunsystemet).
Truberzi must not be given to patients treated with a class of medicines known as potent OATP1B1 inhibitors (such as ciclosporin, a medicine that works on the immune system).
Trudexa 40 mg hver anden uge blev undersøgt i to randomiserede, 24 ugers dobbelt-blinde placebo- kontrollerede forsøg med 393 patienter med aktiv ankyloserende spondylitis (gennemsnits score ved baseline for sygdomsaktivitet [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] var 6,3 i alle grupper), som ikke havde responderet tilstrækkeligt på konventionel behandling.
Trudexa 40 mg every other week was assessed in 393 patients in two randomised, 24 week double−blind, placebo−controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.
Trudexa 40 mg injektion Subkutan anvendelse
Trudexa 40 mg injection Subcutaneous use
Trudexa 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte Adalimumab
Trudexa 40 mg solution for injection in pre-filled syringe Adalimumab
Trudexa 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte leveres som en steril opløsning med 40 mg adalimumab, der er opløst i 0,8 ml opløsning.
Trudexa 40 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution.
Trudexa 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte med beskyttelseshætte Adalimumab
Trudexa 40 mg solution for injection in pre-filled syringe with needleguard Adalimumab
Trudexa 40 mg injektionsvæske, opløsning i hætteglas Adalimumab
Trudexa 40 mg solution for injection in vials Adalimumab
Trudexa blev undersøgt hos 5293 patienter i kontrolleredeog åbne forsøg i op til 60 måneder.
Trudexa was studied in 5293 patients in controlled and open label trials for up to 60 months.
Trudexa bør altid anvendes i nøje overensstemmelse med, hvad Deres læges har fortalt Dem.
Always take Trudexa exactly as your doctor has told you.
Trudexa bør ikke anvendes, hvis De har moderat til alvorlig hjerteinsufficiens.
Trudexa should not be used if you have moderate to severe heart failure.
Trudexa er indiceret til behandling af svær, aktiv Crohns sygdom hos patienter, som på trods af en adækvat behandling med glukokortikoid og/eller et andet immunosuppressivum ikke har responderet tilfredsstillende, eller som er intolerante over for eller har medicinske kontraindikationer mod sådanne behandlinger.
Trudexa is indicated for treatment of severe, active Crohn’s disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Trudexa fyldt pen 40 mg injektionsvæske, opløsning i fyldt pen Adalimumab
Trudexa Pre-filled Pen 40 mg solution for injection in pre-filled pen Adalimumab
Trudexa fyldt sprøjte er en glas spprøjte indeholdende en opløsning af adalimumab.
The Trudexa pre-filled syringe is a glass syringe with needleguard containing a solution of adalimumab.
Trudexa hætteglas er et hætteglas lavet af glas med en opløsning af adalimumab.
The Trudexa vial is a glass vial containing a solution of adalimumab.
Trudexa kan forårsage reaktivering af HBV hos mennesker, der bærer denne virus.
HBV in people who carry this virus.
Trudexa kontraindikeres ved moderat til
Trudexa is contraindicated in moderate to severe
Trudexa leveres også som fyldt injektionssprøjte og fyldt pen.
Trudexa is also available as a pre-filled syringe or a pre-filled pen.
Trudexa leveres også som hætteglas og en fyldt pen.
Trudexa is also available as a vial or a pre-filled pen.
Trudexa leveres også som hætteglas og en fyldt pen..
Trudexa is also available as a vial or a pre-filled pen.
Trudexa n=274 (95% konfidens- interval)
Trudexa n=274 (95% confidence interval)
Trudexa, 40 mg injektion Subkutan anvendelse
Trudexa 40 mg injection Subcutaneous use
Trudexa, 40 mg injektionsvæske, opløsning Adalimumab
Trudexa 40 mg solution for injection Adalimumab
Trudexa, 40 mg injektionsvæske, opløsning i fyldt engangssprøjte (type 1-glas) til patientbrug: Pakninger af:
Trudexa 40 mg solution for injection in single-use pre-filled syringe (type I glass) for patient use: Packs of:
Trudexa, 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte
Trudexa 40 mg solution for injection in pre-filled syringe
Trudexa, 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte Adalimumab
Trudexa 40 mg solution for injection in pre-filled syringe Adalimumab
Trudexa, 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte med beskyttelseshætte Adalimumab
Trudexa 40 mg solution for injection in pre-filled syringe with needleguard Adalimumab
Trudexa, 40 mg injektionsvæske, opløsning i fyldt injektionssprøjte med beskyttelseshætte.
Trudexa 40 mg solution for injection in pre-filled syringe with needleguard
Trudexa, 40 mg injektionsvæske, opløsning i fyldt pen
Trudexa 40 mg solution for injection in pre-filled pen
Trudexa, 40 mg injektionsvæske, opløsning i fyldt pen Adalimumab
Trudexa 40 mg solution for injection in pre-filled pen Adalimumab
Trudexa, 40 mg injektionsvæske, opløsning i hætteglas leveres som en steril opløsning med 40 mg adalimumab, der er opløst i 0,8 ml opløsning.
Trudexa 40 mg solution for injection in vials is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution.
Trudexa, 40 mg injektionsvæske, opløsning.
Trudexa 40 mg solution for injection.
Trudexa-sprøjter må ALDRIG genbruges.
The Trudexa syringe should NEVER be reused.
Trudexas udseende og pakningsstørrelse
What the Trudexa pre-filled pen looks like and contents of the pack
Trudexas udseende og pakningsstørrelse
What the Trudexa pre-filled syringe looks like and contents of the pack
Trulicity 0,75 mg injektionsvæske
Trulicity 0.75 mg solution for injection
Trulicity 0,75 mg injektionsvæske, opløsning i en fyldt injektionssprøjte
Trulicity 0.75 mg solution for injection in pre-filled syringe
Trulicity 0,75 mg injektionsvæske, opløsning i fyldt injektionssprøjte. dulaglutid
Trulicity 0.75 mg solution for injection in pre-filled syringe dulaglutide
Trulicity 0,75 mg injektionsvæske, opløsning i fyldt pen dulaglutid
Trulicity 0.75 mg solution for injection in pre-filled pen dulaglutide
Trulicity 0,75 mg injektionsvæske, opløsning i fyldt pen. dulaglutid
Trulicity 0.75 mg solution for injection in pre-filled pen dulaglutide
Trulicity 0,75 mg: Hver fyldt injektionssprøjte indeholder 0,75 mg dulaglutid i 0,5 ml opløsning.
Trulicity 0.75 mg: Each pre-filled syringe contains 0.75 mg of dulaglutide in 0.5 ml solution.
Trulicity 0,75 mg: Hver fyldt pen indeholder 0,75 mg dulaglutid i 0,5 ml opløsning.
Trulicity 0.75 mg: Each pre-filled pen contains 0.75 mg of dulaglutide in 0.5 ml solution.
Trulicity 1,5 mg injektionsvæske
Trulicity 1.5 mg solution for injection
Trulicity 1,5 mg injektionsvæske, opløsning i en fyldt injektionssprøjte
Trulicity 1.5 mg solution for injection in pre-filled syringe